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Abstract
The T-cell lymphoproliferative disorders are a heterogeneous group of non-Hodgkin’s lymphomas (NHL) for which
current therapeutic strategies are inadequate, as most patients afflicted with these NHL will succumb to disease
progression within 2 years of diagnosis. Appreciation of the genetic and immunologic landscape of these aggressive
NHL, including PD-L1 (B7-H1, CD274) expression by malignant T cells and within the tumor microenvironment,
provides a strong rationale for therapeutic targeting this immune checkpoint. While further studies are needed, the
available data suggests that responses with PD-1 checkpoint blockade alone will unlikely approach those achieved in
other lymphoproliferative disorders. Herein, we review the unique challenges posed by the T-cell lymphoproliferative
disorders and discuss potential strategies to optimize checkpoint blockade in these T-cell derived malignancies.
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Background
The resurgent interest in the tumor microenvironment,
particularly its role in immunosurveillance, and cancer
immunotherapy in the past several years may be largely
attributed to the successes achieved with immune-
checkpoint blockade (CPB) in multiple solid tumors [1].
Like many solid tumors, most non-Hodgkin’s lymphomas
(NHL) are, to varying degrees [2], infiltrated by lymphoid-
and myeloid-derived cell subsets that contribute to either
immune evasion or immunosurveillance [3]. Genomic
alterations involving the PD-L1 (B7-H1, CD274) locus,
particularly gene amplification, lead to significant PD-L1
expression in subsets of aggressive B-cell NHL [4–6],
while lymphoma-associated macrophages within the tumor
microenvironment are an abundant source of PD-L1 in
others [7, 8]. Evidence implicating PD-L1 in immune eva-
sion among common B-cell NHL, in conjunction with the
high response rates, as high as 87%, observed in relapsed
or refractory Hodgkin’s lymphoma with PD-1 CPB [9–11],
provides a strong rationale for this approach in B-cell
NHL. While many studies are ongoing, response rates
exceeding ≈ 33% have been observed in both diffuse
large B-cell and follicular lymphomas [12–14].
In contrast to these more common B-cell NHL which
are curable or controllable with the existing smorgasbord
of therapeutic options, including immunochemotherapy
and targeted or immunomodulatory agents, T-cell derived
NHL, which account for ≈ 10% of NHL in North America,
remain an unmet need, as most patients afflicted with
these aggressive mature (peripheral) T-cell lymphomas
will succumb to their disease within 2 years of diagnosis
[15, 16]. Among peripheral T-cell lymphoma (PTCL) pa-
tients ineligible for high-dose therapy and autologous
stem-cell transplantation at the time of relapse or pro-
gression, median overall survival is less than 6 months
[17, 18]. The long-term outlook for patients with advanced-
stage cutaneous T-cell lymphomas (CTCL) is similarly
discouraging, as durable remissions are rare with exist-
ing therapies [19], and median overall survival for those
with nodal and/or visceral organ involvement is 1–2 years
[20]. Novel therapeutic strategies are urgently needed and
clinical trial participation is encouraged for patients
afflicted with these T-cell derived NHL.
In a large (n = 155) CTCL/PTCL series [21], PD-L1
was expressed by lymphoma cells in 27% of CTCL and
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15% of PTCL, but PD-L1 expression within the tumor
microenvironment was more common, being observed
in 73% and 39% of CTCL and PTCL cases, respectively.
Recently described subsets of PTCL, not otherwise speci-
fied (PTCL, NOS), the most common PTCL subtype in
North America [16], produce an abundance of interferon-γ,
a potent inducer of PD-L1 expression [22, 23]. Approxi-
mately 25% of adult T-cell leukemia/lymphomas (ATLL), a
rare PTCL subtype in most of North America, highly
express PD-L1 due to the aberrant truncation of the 3′
untranslated region of PD-L1 mRNA, leading to increased
stability of the PD-L1 transcript [24]. Alternatively, trans-
locations culminating in the expression of an NPM-ALK
fusion protein in ALK+ anaplastic large cell lymphomas
(ALCL) lead to STAT3-dependent PD-L1 expression
[reviewed in [25]]. As responses to PD-1/PD-L1 CPB are
associated with PD-L1 expression in other tumors, these
observations reasonably contributed to optimism for CPB
in these T-cell derived NHL. The responses observed to
date with this strategy, while encouraging, certainly do
not approach those achieved in Hodgkin’s lymphoma,
and may suggest that CPB in these NHL will require fur-
ther optimization in future studies. Herein, we will review
the limited clinical data available to date, discuss the
unique challenges posed by the T-cell derived NHL, and
suggest strategies for optimization of CPB in these less
common NHL.
Experience with CPB in CTCL/PTCL
While durable remissions with conventional chemo-
therapy are rarely achieved in relapsed/refractory T-cell
NHL [17–19], durable remissions are achieved with
immunomodulatory therapies, including extracorporeal
photopheresis (ECP) and interferon-α [reviewed in [26]].
While largely anecdotal, these observations suggest that
host immunity, when properly harnessed, can lead to dur-
able responses in selected patients. These observations,
coupled with high-level PD-L1 expression in a substantial
minority of patients, further provide a strong rationale for
CPB in CTCL/PTCL. While few of these patients have
been included in early phase clinical trials and further ex-
perience with CPB in CTCL/PTCL is needed, few durable
responses have been observed to date. Twenty-three
CTCL/PTCL patients were enrolled in a phase Ib study
with nivolumab in relapsed/refractory hematologic ma-
lignancies [13]. Among heavily pretreated (61% had re-
ceived ≥4 prior therapies) CTCL/PTCL patients enrolled
in this study, no complete remissions and 4 partial remis-
sions were observed, for an overall response rate of 17%
[13]. While the median progression-free survival was 10
weeks for all patients, two responding CTCL patients
achieved responses that were ongoing at 24+ and 50+
weeks. A single PTCL patient achieved a response that
was ongoing at 18+ months. Preliminary data from an
ongoing phase II study with pembrolizumab in relapsed/
refractory mycosis fungoides (MF) and Sezary syndrome
(SS) has been reported [27]. Among 24 patients enrolled,
no complete remissions and eight partial remissions were
observed, for an overall response rate (ORR) of 33%.
Among these responses, four were in MF (44% ORR in
MF) and four in Sezary syndrome (27% ORR in SS). Re-
sponses were observed in advanced-stage MF, including
patients with tumor-stage disease (2/2, ORR 100%) and
large-cell transformation (1/3, ORR 33%). While these
preliminary results are encouraging, improved under-
standing of the genomic and immunologic landscapes
may be needed to further optimize CPB in the T-cell
lymphoproliferative disorders.
Challenges to checkpoint blockade in the T-cell
lymphoproliferative disorders
Genomic complexity and neoantigen load
In addition to PD-L1 expression itself, the burden of non-
synonymous mutations and neoantigens has emerged as
an important biomarker in CPB-treated patients. The fre-
quency of mutations is highly variable across tumor types
(and within a given tumor type). Carcinogen-associated
tumors, most notably melanoma and non-small cell lung
cancer (NSCLC), are associated with both a relatively high
frequency of somatic mutations (≈10/Mb) and superior
response rates to CPB [28] that is likely explained by
immune-mediated destruction of neoantigen-expressing
tumors [29–32]. For example, in melanoma patients
treated with CTLA-4 CPB, a high mutational load was
associated with clinical benefit from CPB [31, 32]. The
overwhelming majority of patients who derived clinical
benefit from CPB had >100 missense mutations, whereas
patients who failed to benefit had a significantly lower mu-
tational burden. A similar association between mutational
burden and response to PD-1 CPB has been observed in
NSCLC [29]. Despite the highly significant association
between mutational and neoantigen load and response
to CPB, this relationship is not absolute.
In contrast to melanoma and NSCLC, most hematologic
malignancies (e.g. acute myelogenous leukemia, chronic
lymphocytic leukemia, multiple myeloma) are associated
with a lower frequency of somatic mutations (≤1/Mb) [28].
Recently performed next-generation sequencing studies
highlight the genomic complexity associated with many
T-cell NHL. Somatic copy number variants (SCNV),
many of which are focal deletions/amplifications, and
novel fusion events, are common in CTCL [33–35]. Cata-
strophic genomic rearrangements in which a chromosomal
region(s) is subject to multiple double-stranded DNA
breaks followed by random reassembly to form a complex
mosaic chromosome, while infrequently observed in most
cancers [36, 37], are highly prevalent in CTCL [33]. These
studies have also implicated ultraviolet B (UVB) radiation
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in CTCL pathogenesis [33–35, 38, 39], as a high frequency
of C > T transitions have been observed, in contrast to the
T > G transversions observed in B-cell lymphproliferative
disorders [40]. Many of these occurred at NpCpC trinucle-
otides, a signature associated with UVB exposure in melan-
oma [40]. In addition to this global genomic complexity,
nonsynonymous point mutations occur in CTCL at a rate
of ≈ 3 mutations/Mb, a rate that is substantially higher
than many other hematologic malignancies [28]. An aver-
age of ≈ 50–100 somatic nonsynonymous mutations are
observed in CTCL, but considerable variability with muta-
tion rates exceeding 300/tumor in some cases have been
appreciated [33–35, 38, 39, 41]. By comparison, the
mutation rate (≈25/tumor) appears to be lower in PTCL
[42, 43]. While not uniformly reported, these studies sug-
gest that the mutational load varies by histology and dis-
ease stage. For example, a nonsynonymous mutation rate
exceeding 5/Mb was observed in 29% (5/17) of CTCL tu-
mors that had undergone large-cell transformation [38].
This mutation rate exceeds that observed in most lympho-
proliferative disorders, and approaches that observed in
many melanomas [28]. Therefore, distinct subsets of
T-cell NHL likely possess a mutational burden that ri-
vals that associated with clinical benefit from CPB in
solid tumors like melanoma and NSCLC.
In addition to mutational burden and the presentation
of clonal neoantigens [30], specific mutations, including
those that are prevalent in selected T-cell NHL, may
confer susceptibility to CPB. In an effort to understand
the mechanisms involved in acquired resistance to CPB,
Zaretsky et. al. performed whole-exome sequencing in
paired initial and relapsing biopsies from four melanoma
patients. Loss-of-function mutations in JAK1 and JAK2,
associated with diminished responsiveness to interferon-γ
induced PD-L1 expression, were observed in two patients
[44]. Conversely, amplification of the JAK2 locus and en-
hanced JAK/STAT signaling promotes PD-L1 expression
in selected B-cell malignancies [6, 45]. Therefore, gain-of-
function mutations and other genetic alterations that pro-
mote JAK/STAT signaling in selected PTCL subtypes may
confer susceptibility to CPB [reviewed in [46]]. Of course,
the incorporation of genomic data in future and ongoing
CPB trials will be required to address this question
and may improve the ability to identify “exceptional
responders”.
In contrast to other tumor types, including the B-cell
lymphomas, the T-cell lymphomas are derived from the
very cell types (e.g. effector T cells) that are required for
CPB-mediated tumor eradication. Consequently, when
considering CPB within this context, “the world turned
upside down”. For example, recurrent mutations in both
the CD28 extracellular and intracytoplasmic domains
have been observed in a minority of PTCL [42, 47], and
more recently in MF/SS [33, 38]. Mutations in the
extracellular domain increase the binding affinity to
CD28 ligands, particularly CD86 [33]. Whether CTLA-4
blockade, by increasing the availability of CD28 ligands
within the tumor microenvironment, may promote the
growth of malignant T cells harboring these rare mutations
is unknown. Similarly, a rare in-frame fusion between the
extracellular and transmembrane domain of CTLA-4 and
the intracytoplasmic domain of CD28 has been observed,
and presumably exploits the high-affinity ligand-binding
domain of CTLA-4 to activate CD28 signaling [38, 39, 48].
A rapid, transient response was observed in one patient
harboring this novel translocation following therapy with
ipilimumab [48]. While PD-1 is highly expressed is many
CTCL and TFH-derived PTCL [25, 49], it is also recurrently
deleted in a subset of CTCL [38], but the implications of
these observations for PD-1 CPB are uncertain.
The T-cell repertoire
While varying degrees of disease- and treatment-related
immune suppression are observed in most hematologic
malignancies (after all, these are cancers derived from
immune cells that reside in primary and/or secondary
lymphoid organs). Immune suppression observed in patients
with advanced-stage T-cell lymphomas may be profound. In
fact, infectious complications, including opportunistic
infections, are a common cause of death in patients
with advanced-stage CTCL [26]. In conjunction with age-
related immune senescence, malignant T cells may com-
pete with their conventional counterparts. Among patients
with CTCL, particularly patients with Sezary syndrome,
malignant T cells win this homeostatic tug-of-war, as the
normal T-cell repertoire is severely restricted, resembling
that observed in HIV [50], and thymic output dimished
[51]. However, anecdotal evidence suggests that T-cell di-
versity may be restored among patients who achieve a re-
mission with lymphoma-directed therapies [52]. This loss
of T-cell diversity and a restricted T-cell repertoire may
pose a significant challenge for CPB in selected patients.
However, high-dose chemotherapy and autologous stem-
cell transplantation (HDT-ASCT) is frequently employed
as a consolidation strategy among patients with the more
common peripheral T-cell lymphomas who achieve a
first remission. While the T-cell repertoire following
HDT-ASCT has not been scrutinized in these patients,
the post-transplant period may be an opportune time
for CPB given the improved effector to tumor cell ratio
achieved post-transplant.
The tumor microenvironment (TME)
In contrast to most solid tumors, the “tumor” micro-
environment for most T-cell lymphomas includes sec-
ondary lymphoid organs. The architectural effacement of
involved lymph nodes undoubtedly contributes to the
suppression of anti-tumor immunity and global immune
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suppression. Fibroblastic reticular cells (FRC) not only
provide the structural scaffolding required for a function-
ally competent lymph node, but they also produce chemo-
kine gradients (e.g. CCL19, CCL21) and homeostatic
cytokines (e.g. IL-7) that are required for proper choreog-
raphy of the adaptive immune response and homeostatic
survival of naïve T cells [53]. Emerging evidence suggests
that tumor-induced changes in the FRC network contrib-
ute to immune suppression [54], and may pose a challenge
to CPB in lymphoproliferative disorders that are associ-
ated with widespread nodal involvement.
In addition to a disordered lymph node microenvir-
onment, distinct T-cell lymphoma subsets are derived
from populations of “regulatory” T cells that normally
function to restrain T-cell immunity and hamper tumor-
specific immunity [e.g. FoxP3+ Treg cells, [26, 55, 56]].
More recently, a significant proportion of PTCL, NOS
were shown to highly express the Th2-associated transcrip-
tion factor GATA-3 and Th2-associated cytokines, both of
which may contribute to the expansion and functional
polarization of immunosuppressive lymphoma-associated
macrophages [22, 23]. Similarly, a subset of PTCL (i.e.
angioimmunoblastic T-cell lymphomas) express the tran-
scriptional repressor Bcl-6 and are TFH-cell derived. These
TFH-derived lymphomas are associated with an expanded
population of B-cell immunoblasts. The extent to which
these B cells have regulatory properties is poorly under-
stood [57]. Therefore, in addition to structural alterations
in secondary lymphoid organs, the “cell of origin” from
which a malignant T cell is derived dramatically alters the
TME in a manner that is likely relevant for CPB and other
immunomodulatory therapies [46].
In addition to those characteristics of the TME that
are likely most relevant for the lymphoproliferative dis-
orders generally, and the T-cell lymphomas specifically,
the TME in most T-cell lymphomas, like many solid tu-
mors, includes expanded populations of myeloid-derived
cells, most notably lymphoma-associated macrophages
(LAM) and eosinophils. As in other tumor types, LAM
impair tumor-specific immunity in the T-cell lymph-
omas, in part, by their expression of PD-L1 [21]. While
the role of lymphoma-associated eosinophils (LAE) in
PTCL is poorly understood, their shear abundance in
many of these lymphomas coupled with their ability to
suppress T-cell immunity in other contexts suggests that
LAE may be relevant players within the TME and may
impede CPB [58–60]. In addition to its role in sup-
pressing cytotoxic T-cell-mediated cytotoxicity, PD-L1
promotes the generation of induced Tregs within the
TME [21]. And, of course, constituents of the TME un-
doubtedly provide additional co-inhibitory ligands that
engage additional immune checkpoints that are not yet
characterized in T-cell lymphoproliferative disorders
[61]. Given these challenges imposed by the TME, it
seems quite likely that CPB as a single therapeutic modal-
ity may be further optimized by the incorporation of com-
plementary therapeutic strategies that may overcome the
barriers to effective tumor immunity following CPB alone
in the T-cell lymphomas.
Combination strategies for optimizing checkpoint
blockade
Immunomodulatory agents
Lenalidomide is an immunomodulatory derivative (IMiD)
with pleiotropic immunomodulatory effects and clinical
activity in many hematologic malignancies. Lenalidomide
promotes natural killer (NK) cell function [62, 63],
stimulates T-cell proliferation and IL-2 production [64],
promotes Th1-biased immunity [65], abrogates PD-L1
induced inhibition of NK and T-cell functions [66], and
may thus augment responses observed with checkpoint
blockade [67]. Multiple co-inhibitory ligands collabor-
ate to impair formation of an organized immunologic syn-
apse between malignant lymphocytes and effector T cells
[66]. Impaired formation of the immunologic synapse is
abrogated by lenalidomide [66]. The immunomodulatory
effects observed in T cells exposed to lenalidomide are
likely mediated by cereblon-dependent proteasomal
degradation of Ikaros family transcription factors [64].
Interleukin-10 is secreted by malignant T cells and pro-
motes immune evasion in PTCL [22, 68], and its ex-
pression in CD4+ T cells is positively regulated by
Ikaros [69], likely explaining the mechanism by which
lenalidomide impairs IL-10 production in malignant T
cells (unpublished observation). A multicenter phase 2
study in patients with relapsed/refractory PTCL (n = 54)
treated with single-agent lenalidomide demonstrated an
overall response rate of 22% (11% CR). Stable disease was
observed in 30%, for an overall tumor control rate of 52%
[70]. Therefore, lenalidomide and CPB may be rationally
combined in T-cell NHL.
Recurrent mutations or deletions in chromatin remod-
eling proteins (e.g. SWI/SNF complex) or histone (e.g.
deacetylases) and DNA (e.g. methyltransferases) modifying
enzymes are commonly observed in many T-cell NHL. Al-
terations in these epigenetic modifiers have been observed
in >90% of CTCL and may explain, at least in part, the
clinical activity associated with histone deacetylase inhibi-
tors (HDACi) in these lymphomas [34]. Three HDACi are
currently FDA approved for use in various T-cell NHL,
with overall response rates from 25–30% being observed
[71–73]. Histone deacetylases, by epigenetically regulating
gene expression, regulate the differentiation, activation
and effector functions of conventional lymphocytes [74].
Not surprisingly then, HDAC inhibitors have pleiotropic
immunomodulatory effects. While the mechansims and
specific HDAC’s involved are poorly understood, HDAC
inhibition may promote tumor antigen presentation and
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T-cell costimulation [75–78], conferring increased suscep-
tibility to cell-mediated cytotoxicity [79]. These observa-
tions are relevant, as loss of antigen presentation may be
an important mechanism of acquired resistance to CPB
[44]. Various HDAC inhibitors have been shown to either
promote, or in some cases suppress, the function of con-
ventional and regulatory T cells and myeloid-derived cells
[reviewed in [80]]. These effects are likely dependent upon
the agent used and the specificity for its targets at the dose
and schedule utilized. Nonetheless, Zheng et. al. recently
demonstrated using a murine NSCLC model that romi-
depsin significantly increased the production of chemo-
kines required for T-cell trafficking [81]. Therefore, when
combined with CPB, romidepsin led to a significant in-
crease in tumor-infiltrating lymphocytes and improved
disease control in this model. A similar mechanism was
recently invoked in an ovarian cancer model [82]. In this
model, epigenetic silencing of the same chemokines exam-
ined by Zheng et. al. (CXCL9, CXCL10) was associated
with poor outcomes with CPB. However, treatment with a
hypomethylating agent reversed this epigenetic silencing,
increased migration of effector T cells to the tumor site,
and significantly improved the efficacy of CPB [82]. These
insights, combined with the now well-established activity
and favorable toxicity profile of the HDAC inhibitors in
clinical use, provide a strong rationale for combination
strategies incorporating these agents.
Maturation of tumor-associated dendritic cells (DC) is
required for trafficking to tumor-draining lymph nodes
and optimal antigen-presentation, but is often impaired
within the TME. Despite a robust infiltrate of DC in
many T-cell NHL, their maturation is impaired in an
IL-10-dependent manner [68]. Therefore, strategies that
promote DC maturation within the TME may promote
anti-tumor immunity. DC maturation is regulated by
receptors, including toll-like receptors (TLR), that sense a
broad spectrum of “danger signals”. For example, TLR8 is
expressed by DCs within human skin and promotes their
activation in response to viral ssRNA [83]. Resiquimod, an
imidazoquinoline that is a potent TLR8 (and TLR7)
agonist, is available as a topical gel and was investigated
in patients with limited-stage CTCL [84]. In this study,
resiquimod was topically applied to 4–5 target lesions
in 12 patients. Complete resolution of all treated lesions
was observed in 30% of patients and was associated with
DC maturation and the recruitment of activated T cells.
More impressively, this therapy was associated with
complete resolution of all disease, including untreated
lesions, in two patients. A similar strategy has been
employed with an intratumorally injected TLR9 agonist
combined with radiation [85]. These observations suggest
that CPB may be improved by strategies that augment in-
nate immunity and bolster antigen presentation, leading
to more effective priming of antigen-specific T cells. As
the skin is a commonly involved extranodal site of disease
in many PTCL, these findings may have therapeutic appli-
cations, in combination with CPB, that extend beyond
CTCL.
Targeted agents
Novel agents targeting a number of tyrosine kinases,
including those that are required for antigen-receptor
signaling in malignant lymphocytes, are increasingly
being utilized, and are now FDA approved, in various
hematologic malignancies. The role of these novel agents,
and their targets, in the T-cell lymphoproliferative disor-
ders is poorly understood, but is the subject of ongoing
pre-clinical and clinical studies [46, 86]. More recently, we
observed that TCR activation in primary T-cell lymphoma
cells had a profound effect on gene expression, as ≈ 1000
genes were significantly upregulated following TCR en-
gagement, including those that regulate cell growth and
survival [87]. Engagement of the TCR by either antibody
cross-linking or major histocompatibility complex pro-
teins expressed by autologous lymphoma-associated
macrophages increased T-cell lymphoma proliferation
and increased resistance to chemotherapeutic agents in
primary specimens. The Tec family kinase, and BTK
homologue, ITK plays a pivotal role in proximal TCR
signaling [reviewed in [88]]. Given their high homology,
it may not be surprising that the BTK inhibitor ibruti-
nib also inhibits ITK in normal T cells [89]. Therefore,
ITK inhibition has emerged as a novel therapeutic strategy
in the T-cell NHL, and is the subject of an ongoing clinical
trial. However, in addition to its direct effect on malignant
T cells, ITK inhibition may also have relevant immuno-
modulatory effects, as ITK qualitatively regulates TCR sig-
naling and negatively regulates the expression of T-bet,
and is thus required for optimal Th2-biased immunity
[90]. Consequently, established Th2 cells are increasingly
dependent upon ITK, as the Th2-associated transcription
factor GATA-3 promotes the selective downregulation of
RLK, a TEC family kinase that is, at least partially, redun-
dant with ITK. Therefore, in contrast to Th1 cells, that are
associated with effective anti-tumor immunity, Th2 cells,
due to a relative abundance of ITK compared with RLK
(i.e. a high ITK/RLK ratio), are particularly sensitive to
ibrutinib, which does not inhibit RLK. Therefore, ibrutinib
therapy in murine models is associated with enhanced
Th1-biased immunity [89], and augments CPB [91].
Tumor-antigen release and presentation is a prerequis-
ite for adaptive T-cell immunity and the emergence of
T-cell anergy or exhaustion. Therefore, T-cell “ignorance”
may be fostered by non-immunogenic forms of cell death
in some tumors [92, 93], and pose a barrier to effective
CPB. In contrast, immunogenic forms of cell death (ICD)
are associated with the unveiling of various “danger sig-
nals” that foster antigen uptake, presentation, and the
Phillips et al. Journal for ImmunoTherapy of Cancer  (2016) 4:95 Page 5 of 10
induction of T-cell immunity [94]. A number of “con-
ventional” therapies, including selected chemotherapeu-
tic agents and radiation [95, 96], are potent inducers of
ICD, and may augment CPB if properly sequenced. For
example, radiation of a single tumor may initiate an
anti-tumor immune response, culminating in the eradica-
tion of distant tumor deposits when used in conjunction
with CPB [97, 98]. While definitive radiation therapy is
used infrequently in most T-cell NHL, palliative radiation
therapy is frequently utilized in tumor-stage CTCL.
Tumor cell autophagy (“self-eating”) promotes the release
of “danger signals” and tumor antigens required for ICD.
Therefore, impaired autophagy abrogates chemotherapy-
induced ICD and anti-tumor immunity, while the induc-
tion of autophagy promotes ICD [99, 100]. Therapeutic
strategies that induce autophagy may be rationally com-
bined with CPB. The mammalian target of rapamycin
(mTOR), in response to nutritional and environmental
cues, regulates a number of growth and survival pathways
in cancer, including T-cell NHL [23, 101], and negatively
regulates autophagy [102]. Responses following mTOR in-
hibition have been observed in patients with relapsed/re-
fractory T-cell NHL, and by promoting autophagy and
ICD may be rationally combined with both HDAC inhibi-
tors and CPB [101, 103–105].
Targeting the tumor microenvironment
Gene expression by lymphoma-associated macrophages
(LAM) and their density within the TME explains the
variable natural history associated with many NHL [3].
LAM are abundant constituents of the TME in PTCL,
where they promote chemotherapy resistance and sup-
press anti-tumor immunity [22, 46, 68]. Upon activation
and differentiation, normal CD4+ T cells produce cyto-
kines that regulate LAM biology, including type 1 (IFN-γ)
and type 2 (IL-4, IL-13) cytokines, which lead to “classical”
and “alternative” pathways of LAM activation and func-
tional polarization, respectively. Cytokines produced by
malignant T cells similarly promote LAM recruitment/
expansion within the TME [68], their functional (“alter-
native”) polarization [22], and PD-L1 expression [21].
Thus, depletion of LAM in the T-cell lymphomas may
not only impair the growth and survival of malignant T
cells, but reverse immune suppression within the TME.
While a number of tumor-derived factors have been im-
plicated in the recruitment and survival of LAM, colony-
stimulating factor-1 (CSF-1, or M-CSF) is required for
normal macrophage homeostasis and viability. Mice lack-
ing functional CSF-1 or nullizygous for CSF-1 receptor
(CSF-1R, c-fms, CD115) have a marked decrease in tissue
resident macrophages. More importantly, CSF-1R block-
ade prevents the generation of LAM in a variety of
hematologic malignancies [106]. Therefore, inhibition of
CSF-1R has emerged as a rational therapeutic strategy in
many solid tumors and hematologic malignancies
[107–111]. Therefore, depletion of LAM from the TME
may augment the efficacy of novel immunotherapies, in-
cluding CPB [112]. Second only to LAM, eosinophils are
arguably an abundant subset of myeloid-derived cells in
many T-cell NHL. While their role in these lymphomas is
poorly understood, eosinophils are an abundant source of
indoleamine 2,3 dioxygenase (IDO) [58], the rate-limiting
enzyme in catabolism of the essential amino acid trypto-
phan. As tryptophan is required for optimal T-cell im-
munity, IDO is an alternative “checkpoint” within the
TME that may confer resistance to CPB [113].
The chemokine receptor CCR4 is preferentially expressed
by Th2 and Treg cells and promotes their migration to
extranodal sites, including the skin, in response to its li-
gands (CCL17, CCL22). CCR4 is widely expressed in
CTCL and a recently described subset of PTCL, NOS
[22]. The CCL17/CCL22 - CCR4 axis in CTCL is main-
tained by the absence of CD26, a dipeptydilpeptidase,
which inactivates CCR4 ligands. Recently described gain-
of-function mutations in the CCR4 cytoplasmic domain
inhibit CCR4 internalization and promote PI3K/AKT acti-
vation. These mutations were recently described in ≈ 25%
of adult T-cell leukemia/lymphomas and in CTCL
[38, 114]. Therefore, CCR4 has a pathogenic role in
selected T-cell NHL and has been the subject of on-
going investigations with the anti-CCR4 monoclonal
antibody mogamulizumab. This glycoengineered monoclo-
nal antibody depletes CCR4-expressing cells by antibody-
dependent cell-mediated cytotoxicity (ADCC), and has sig-
nificant clinical activity in CCR4+ T-cell NHL [115–117].
However, in addition to directly targeting malignant T cells,
mogamulizumab depletes Tregs in these patients [116, 118]
Therefore, mogamulizumab, by depleting malignant T cells
and Tregs, effectively kills “two birds with one stone” in the
T-cell NHL [119]. Not surprisingly, Treg depletion with this
agent has been associated with improved anti-tumor im-
munity [120, 121], and future studies in combination with
CPB in the T-cell NHL are warranted.
Conclusions
Conventional chemotherapeutic strategies are not
curative for the majority of patients with T-cell lym-
phoproliferative disorders. This may be explained by
both cell-autonomous and non-cell-autonomous mecha-
nisms of chemotherapy resistance. Prior to the dawn of
the new era in immunotherapy and immune checkpoint
blockade, chemotherapy was similarly ineffective in meta-
static melanoma, but durable remissions, if not cure, are
now achieved with checkpoint blockade in this disease.
Improved understanding of the genetic landscape in the
T-cell lymphomas and the use of novel targeted agents,
while welcome additions to the therapeutic armament-
arium, are unlikely to be curative for most patients
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with these aggressive lymphomas. In contrast, further
optimization of checkpoint blockade, and other immu-
notherapeutic strategies, combined with kinase inhibi-
tors, immunomodulatory agents, or therapies targeting
the epigenome offer the hope that conventional multi-
agent chemotherapy may be replaced by well tolerated
therapies with curative potential for patients afflicted
with these aggressive lymphomas.
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